Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3699650 | 0.88 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL860823 | 0.87 | TLR7 (0.76) | TLR7TLR8 | |
| SCHEMBL16568337 | 0.82 | TLR7 (0.76) | TLR7TLR8 | |
| SCHEMBL16568336 | 0.82 | TLR7 (0.76) | TLR7TLR8 | |
| SCHEMBL4206271 | 0.79 | TLR7 (0.88) | TLR7TLR8 | |
| SCHEMBL4198142 | 0.79 | TLR7 (0.88) | TLR7TLR8 | |
| SCHEMBL12343252 | 0.77 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL20212147 | 0.76 | TLR7 (0.63) | TLR7 | |
| SCHEMBL20212146 | 0.76 | TLR7 (0.63) | TLR7 | |
| SCHEMBL31410723 | 0.76 | TLR7 (0.63) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122867-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | ASTRAZENECA UK LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122867-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | TYMS, TYMP, DPYD | TLR7 2123/4885TLR8 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.